Mineralys Therapeutics Inc (NASDAQ: MLYS) kicked off on Tuesday, down -3.61% from the previous trading day, before settling in for the closing price of $36.83. Over the past 52 weeks, MLYS has traded in a range of $8.24-$47.65.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -170.42%. While this was happening, its average annual earnings per share was recorded 35.17%. With a float of $56.37 million, this company’s outstanding shares have now reached $78.97 million.
Mineralys Therapeutics Inc (MLYS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 28.77%, while institutional ownership is 79.50%. The most recent insider transaction that took place on Nov 20 ’25, was worth 43,350,000. In this transaction Director of this company sold 1,000,000 shares at a rate of $43.35, taking the stock ownership to the 7,903,838 shares. Before that another transaction happened on Nov 20 ’25, when Company’s Affiliate proposed sale 1,000,000 for $42.12, making the entire transaction worth $42,120,000.
Mineralys Therapeutics Inc (MLYS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.98 earnings per share (EPS), higher than consensus estimate (set at -1.08) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 35.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.46% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Take a look at Mineralys Therapeutics Inc’s (MLYS) current performance indicators. Last quarter, stock had a quick ratio of 25.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.96, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -2.19 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
The latest stats from [Mineralys Therapeutics Inc, MLYS] show that its last 5-days average volume of 0.99 million was inferior to 1.21 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 34.22%.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 65.35%, which indicates a significant increase from 9.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.71 in the past 14 days, which was lower than the 2.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $40.03, while its 200-day Moving Average is $24.94. Now, the first resistance to watch is $36.56. This is followed by the second major resistance level at $37.61. The third major resistance level sits at $38.33. If the price goes on to break the first support level at $34.79, it is likely to go to the next support level at $34.07. The third support level lies at $33.02 if the price breaches the second support level.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
The company with the Market Capitalisation of 2.81 billion has total of 79,140K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -177,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -36,930 K.
